home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

New Compounds Offer Promise For Diabetes Treatment

  December, 13 2007 10:00
your information resource in human molecular genetics

Drug researchers have identified a new class of molecule that could help to tackle diabetes, and which mimic the beneficial metabolic effects of a reduced-calorie diet. The compounds activate the same pathway targeted by resveratrol, the compound thought to deliver many of the proposed health benefits of red wine and grapes.

The new compounds are roughly 1,000 times more potent than resveratrol at activating a molecule called SIRT1, which functions to ensure that the body remains receptive to the activity of the hormone insulin. They are therefore more potent at staving off the development of type 2 diabetes. Obese mice treated with the compounds showed improved insulin sensitivity and reduced blood glucose levels, report researchers led by Christoph Westphal in Nature.

Although far from entering clinical testing in humans, the compounds potentially offer an important therapeutic avenue for developing treatments to tackle diseases linked to ageing and poor diet, the researchers add.


Christoph Westphal (Sirtris Pharmaceuticals Inc, Cambridge, MA, USA)
E-mail: cwestphal@sirtrispharma.com

(C) Nature press release.

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.